Arie Belldegrun

Arie Belldegrun
Name	Arie Belldegrun
Birth date	1949
Birth place	Jerusalem, Israel
Nationality	Israeli American
Occupation	Oncologist; entrepreneur; investor; urologist
Known for	Founding Allogene Therapeutics; leadership at Agensys; work in prostate cancer; board roles at Weill Cornell Medicine; philanthropy

Arie Belldegrun Arie Belldegrun is an Israeli-American urologist and biotechnology entrepreneur known for translational work in oncology and for founding multiple biotech companies. He combines clinical practice with venture investment and corporate leadership in biotechnology, holding positions at academic centers and private firms. His career spans clinical care at major hospitals, research at institutions, and corporate roles that include company founding, board directorships, and mergers with global pharmaceutical firms.

Early life and education

Belldegrun was born in Jerusalem and emigrated to Canada for medical training, where he attended the McGill University Faculty of Medicine and received surgical and urologic training. He completed residency and fellowship programs at centers including Harvard Medical School-affiliated hospitals and trained under mentors linked to institutions such as Brigham and Women's Hospital and Dana–Farber Cancer Institute. Further postgraduate experience included research fellowships in molecular oncology tied to laboratories at Weill Cornell Medicine and collaborations with researchers from Memorial Sloan Kettering Cancer Center.

Medical and research career

Belldegrun established a clinical practice in urology with a focus on prostate cancer and renal cell carcinoma at academic medical centers in Los Angeles and New York City. He held faculty appointments at institutions including UCLA and later associated with Cedars-Sinai Medical Center and Harvard Medical School-affiliated programs. His research linked translational science from laboratories at Cold Spring Harbor Laboratory and Stanford University to clinical trial design involving targeted therapies from companies such as Genentech and Amgen. He contributed to cooperative group trials coordinated with organizations like the National Cancer Institute and participated in advisory activities for regulatory bodies including the Food and Drug Administration.

Entrepreneurship and biotech ventures

Belldegrun founded and led multiple biotechnology companies, beginning with early-stage ventures such as Agensys, which advanced monoclonal antibodies in partnership with firms like AstraZeneca and Roche. He later founded Allogene Therapeutics, an allogeneic cell therapy company that engaged in collaborations with Fate Therapeutics and strategic transactions involving Astellas and Bristol-Myers Squibb. Other ventures include roles in startups that attracted investment from corporate partners such as Johnson & Johnson and Novartis; he has served as CEO, chairman, or board member for companies that merged with multinational firms including Pfizer and Amgen. Belldegrun also cofounded venture fund initiatives and family office investment vehicles that partnered with firms like Kleiner Perkins and Sequoia Capital focused on life sciences. He sits on boards and advisory committees for companies and institutions including Teva Pharmaceutical Industries and university-affiliated incubators.

Major clinical and scientific contributions

His clinical contributions encompass surgical innovations in minimally invasive radical prostatectomy techniques and management algorithms for metastatic prostate cancer integrating targeted therapies from companies such as Pfizer and AstraZeneca. Scientifically, he promoted translation of monoclonal antibody therapeutics pioneered at companies like Genentech and ImmunoGen into clinical oncology through companies such as Agensys. He supported development programs in immuno-oncology and cell therapy, advancing allogeneic approaches that intersect with science from CAR-T research at Memorial Sloan Kettering Cancer Center and academic translational labs. His work encompassed clinical trial leadership, biomarker-driven patient selection using assays from collaborators like Foundation Medicine and partnerships with diagnostic entities such as Thermo Fisher Scientific.

Awards, honors, and recognitions

Belldegrun has received honors from academic and professional societies, including awards from the American Urological Association and recognitions tied to contributions in oncology from organizations such as the American Association for Cancer Research. He has been listed among industry rankings by publications like Forbes and received philanthropic awards from institutions including Weill Cornell Medicine and Cedars-Sinai. Honorary degrees and lectureships have been conferred by universities including McGill University and other research institutes, and he has been invited to deliver named lectures at meetings organized by bodies such as the European Society for Medical Oncology and the American Society of Clinical Oncology.

Philanthropy and art patronage

Belldegrun and his family philanthropic activities have supported institutions including Weill Cornell Medicine, UCLA Health, and cultural organizations such as the Los Angeles County Museum of Art and museums in Jerusalem. He has funded research centers, endowed chairs, and supported initiatives at cancer research organizations including the Dana–Farber Cancer Institute and educational programs at McGill University. As an art patron, he has collected works associated with galleries and museums in New York City and Los Angeles and contributed to exhibitions at institutions like the Museum of Modern Art and regional art foundations.

Personal life and public profile

Belldegrun is married with children and divides time between residences in Los Angeles and New York City, maintaining ties to Israel and Canada. He appears in business media outlets including The New York Times, The Wall Street Journal, and Bloomberg concerning biotech deals and philanthropy, and has been profiled by publications such as Forbes and The Economist. He participates in conference programming at events hosted by organizations like J.P. Morgan and BIO and serves on advisory boards linking academic research institutions and industry partners including Harvard Medical School and Weill Cornell Medicine.

Category:Physicians Category:Biotechnology founders